Preview

Медицинский Совет

Расширенный поиск

Роль этиотропной терапии в лечении и профилактике осложнений гриппа в условиях пандемии COVID-19

https://doi.org/10.21518/2079-701X-2021-18-86-93

Полный текст:

Аннотация

Грипп остается одним из наиболее распространенных респираторно-вирусных заболеваний, сопровождающихся высоким риском развития осложнений. В условиях пандемии C0VID-19 возникает вероятность одновременной циркуляции двух вирусов, что обуславливает необходимость проведения дифференциальной диагностики. Грипп и C0VID-19 имеют общие пути передачи возбудителя и схожие симптомы, поэтому оптимальным в дифференциальной диагностике является применение тест-систем на оба вируса. На фоне гриппа и C0VID-19 могут развиваться осложнения со стороны различных органов и систем. В статье подробно рассмотрены осложнения гриппа со стороны сердечно-сосудистой системы. После заражения вирусом гриппа происходит 6-10-кратное повышение риска острого инфаркта миокарда и 3-8-кратное повышение риска инсульта. С COVID-19 ассоциированы артериальная гипертензия, сахарный диабет, нарушения ритма сердца, миокардит, высокий риск развития острого инфаркта миокарда, сердечная недостаточность. В статье приведены данные собственных исследований, свидетельствующих, что перенесенное заболевание COVID-19 повышает риск острого коронарного синдрома независимо от наличия факторов риска сердечно-сосудистых событий. Профилактикой развития осложнений гриппа является раннее назначение этиотропной противовирусной терапии. Многочисленные исследования подтверждают эффективность в терапии гриппа ингибитора нейраминидазы осельтамивира. Применение осельтамивира уменьшает выраженность клинических проявлений, сокращает длительность заболевания, снижает риск осложнений и летального исхода. Наиболее эффективной мерой профилактики гриппа и C0VID-19 является специфическая иммунизация. В ряде случаев может быть использована химиопрофилактика. В статье рассмотрены исследования по эффективности химиопрофилактики гриппа с применением ингибиторов нейраминидазы.

Об авторах

Н. В. Орлова
Российский национальный исследовательский медицинский университет имени Н.И. Пирогова
Россия

Орлова Наталья Васильевна – доктор медицинских наук, профессор, профессор кафедры факультетской терапии педиатрического факультета.

117997, Москва, ул. Островитянова, д. 1.



В. В. Ломайчиков
Российский национальный исследовательский медицинский университет имени Н.И. Пирогова
Россия

Ломайчиков Валерий Валерьевич - ассистент кафедры факультетской терапии педиатрического факультета.

117997, Москва, ул. Островитянова, д. 1.



Список литературы

1. Paules C., Subbarao K. Influenza. Lancet. 2017;390(10095):697-708. https://doi.org/10.1016/S0140-6736(17)30129-0.

2. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2019;7(1):69-89. https://doi.org/10.1016/S2213-2600(18)30496-X.

3. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. https://doi.org/10.1001/jama.2020.2648.

4. Bahl P., Doolan C., de Silva C., Chughtai A.A., Bourouiba L., MacIntyre C.R. Airborne or droplet precautions for health workers treating COVID-19? J Infect Dis. 2020;20:1-8. https://doi.org/10.1093/infdis/jiaa189.

5. Qin J., You C., Lin Q., Hu T., Yu S., Zhou X.H. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel crosssectional and forward follow-up study. Sci Adv. 2020;6(33):eabc1202. https://doi.org/10.1126/sciadv.abc1202.

6. Song L., Liang E.Y., Wang H.M., Shen Y., Kang C.M., Xiong Y.J. et al. Differential diagnosis and prospective grading of COVID-19 at the early stage with simple hematological and biochemical variables. Diagn Microbiol Infect Dis. 2021;99(2):115-169. https://doi.org/10.1016/j.diagmicrobio.2020.115169.

7. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. https://doi.org/10.1001/jama.2020.2648.

8. Krati K., Rizkou J., Errami A.A., Essaadouni L. Differential diagnosis of COVID-19 in symptomatic patients at the University Hospital Center Mohammed VI, Marrakesh. Pan Afr Med J. 2020;36:269. https://doi.org/10.11604/pamj.2020.36.269.24558.

9. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-544. https://doi.org/10.1038/s41564-020-0695-z.

10. Macias A.E., McElhaney J.E., Chaves S.S., Nealon J., Nunes M.C., Samson S.I. et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39(1 Suppl.):A6-A14. https://doi.org/10.1016/j.vaccine.2020.09.048.

11. Blackburn R., Zhao H., Pebody R., Hayward A., Warren-Gash C. Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004-2015. Clin Infect Dis. 2018;67(1):8-17. https://doi.org/10.1093/cid/cix1144.

12. Reichert T.A., Simonsen L., Sharma A., Pardo S.A., Fedson D.S., Miller M.A. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol. 2004;160(5):492-502. https://doi.org/10.1093/aje/kwh227.

13. Fischer W.A. 2nd, Gong M., Bhagwanjee S., Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart. 2014;9(3):325-336. https://doi.org/10.1016/j.gheart.2014.08.004.

14. Sellers S.A., Hagan R.S., Hayden F.G., Fischer W.A. 2nd. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372-393. https://doi.org/10.1111/irv.12470.

15. Kwong J.C., Schwartz K.L., Campitelli M.A., Chung H., Crowcroft N.S., Karnauchow T. et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345-353. https://doi.org/10.1056/NEJMoa1702090.

16. Warren-Gash C., Smeeth L., Hayward A.C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9(10):601-610. https://doi.org/10.1016/S1473-3099(09)70233-6.

17. Boehme A.K., Luna J., Kulick E.R., Kamel H., Elkind M.S.V. Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018;5(4):456-463. https://doi.org/10.1002/acn3.545.

18. Nguyen J.L., Yang W., Ito K., Matte T.D., Shaman J., Kinney P.L. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1(3):274-281. https://doi.org/10.1001/jamacardio.2016.0433.

19. Vejpongsa P., Kitkungvan D., Madjid M., Charitakis K., Anderson H.V., Arain S. et al. Outcomes of Acute Myocardial Infarction in Patients with Influenza and Other Viral Respiratory Infections. Am J Med. 2019;132(10):1173-1181. https://doi.org/10.1016/j.amjmed.2019.05.002.

20. Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F.M. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666-1687. https://doi.org/10.1093/cvr/cvaa106.

21. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Heneghan C.J., Hama R., Thompson M. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012;1:CD008965. https://doi.org/10.1002/14651858.CD008965.pub3.

22. Muthuri S.G., Myles P.R., Venkatesan S., Leonardi-Bee J., Nguyen-Van-Tam J.S. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207(4):553-563. https://doi.org/10.1093/infdis/jis726.

23. Muthuri S.G., Venkatesan S., Myles P.R., Leonardi-Bee J., Al Khuwaitir T.S., Al Mamun A. et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. https://doi.org/10.1016/S2213-2600(14)70041-4.

24. Harper S.A., Bradley J.S., Englund J.A., File T.M., Gravenstein S., Hayden F.G. et al. Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-10032. https://doi.org/10.1086/598513.

25. Dommguez-Cherit G., Lapinsky S.E., Macias A.E., Pinto R., Espinosa-Perez L., de la Torre A. et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-1887. https://doi.org/10.1001/jama.2009.1536.

26. Louie J.K., Yang S., Acosta M., Yen C., Samuel M.C., Schechter R. et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1) pdm09. Clin Infect Dis. 2012;55(9):1198-1204. https://doi.org/10.1093/cid/cis636.

27. Lee N., Choi K.W., Chan P.K., Hui D.S., Lui G.C., Wong B.C. et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65(6):510-515. https://doi.org/10.1136/thx.2009.130799.

28. Katzen J., Kohn R., Houk J.L., Ison M.G. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes. Clin Infect Dis. 2019;69(1):52-58. https://doi.org/10.1093/cid/ciy860.

29. Siston A.M., Rasmussen S.A., Honein M.A., Fry A.M., Seib K., Callaghan W.M. et al. Pandemic H1N1 Influenza in Pregnancy Working Group. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303(15):1517-1525. https://doi.org/10.1001/jama.2010.479.

30. Lytras T., Mouratidou E., Andreopoulou A., Bonovas S., Tsiodras S. Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study. Clin Infect Dis. 2019;69(11):1896-1902. https://doi.org/10.1093/cid/ciz101.

31. Ariano R.E., Sitar D.S., Zelenitsky S.A., Zarychanski R., Pisipati A., Ahern S. et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ. 2010;182(4):357-363. https://doi.org/10.1503/cmaj.092127.

32. Eyler R.F., Heung M., Pleva M., Sowinski K.M., Park P.K., Napolitano L.M., Mueller B.A. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012;32(12):1061-1069. https://doi.org/10.1002/phar.1151.

33. Eyler R.F., Klein K.C., Mueller B.A. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. J Pediatr Pharmacol Ther. 2012;17(2):173-176. https://doi.org/10.5863/1551-6776-17.2.173.

34. Giraud C., Manceau S., Oualha M., Chappuy H., Mogenet A., Duchene P. et al. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. Antimicrob Agents Chemother. 2011;55(1):433-435. https://doi.org/10.1128/AAC.00813-10.

35. Kromdijk W., Sikma M.A., van den Broek M.P., Beijnen J.H., Huitema A.D., de Lange D.W. Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. Intensive Care Med. 2013;39(5):977-978. https://doi.org/10.1007/s00134-013-2851-x.

36. Lemaitre F., Luyt C.E., Roullet-Renoleau F., Nieszkowska A., Zahr N., Corvol E. et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit. 2012;34(2):171-175. https://doi.org/10.1097/FTD.0b013e318248672c.

37. Mulla H., Peek G.J., Harvey C., Westrope C., Kidy Z., Ramaiah R. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. Anaesth Intensive Care. 2013;41(1):66-73. https://doi.org/10.1177/0310057X1304100112.

38. Hahn J., Choi J.H., Chang M.J. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J Clin Pharm Ther. 2017;42(6):661-671. https://doi.org/10.1111/jcpt.12636.

39. To K.K., Hung I.F., Li I.W., Lee K.L., Koo C.K., Yan W.W. et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50(6):850-859. https://doi.org/10.1086/650581.

40. Lee N., Chan P.K., Wong C.K., Wong K.T., Choi K.W., Joynt G.M. et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther. 2011;16(2):237-247. https://doi.org/10.3851/IMP1722.

41. Ison M.G., de Jong M.D., Gilligan K.J., Higgs E.S., Pavia A.T., Pierson J. et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis. 2010;201(11):1654-1662. https://doi.org/10.1086/652498.

42. Uyeki T.M., Bernstein H.H., Bradley J.S., Englund J.A., File T.M., Fry A.M. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis. 2019;68(6):e1-e47. https://doi.org/10.1093/cid/ciy866.

43. Lee N., Hurt A.C. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis. 2018;31(6):520-526. https://doi.org/10.1097/QCO.0000000000000498.

44. Greer L.G., Leff R.D., Rogers V.L., Roberts S.W., McCracken G.H. Jr., Wendel G.D. Jr., Sheffield J.S. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol. 2011;204(6 Suppl.):89-93. https://doi.org/10.1016/j.ajog.2011.03.005.

45. Tanaka T., Nakajima K., Murashima A., Garcia-Bournissen F., Koren G., Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ. 2009;181(1-2):55-58. https://doi.org/10.1503/cmaj.090866.

46. Dickey R.P., Xiong X., Xie Y., Gee R.E., Pridjian G. Effect of maternal height and weight on risk for preterm singleton and twin births resulting from IVF in the United States, 2008-2010. Am J Obstet Gynecol. 2013;209(4):349.e1-6. https://doi.org/10.1016/j.ajog.2013.05.052.

47. Saito S., Minakami H., Nakai A., Unno N., Kubo T., Yoshimura Y. Outcomes of infants exposed to oseltamivir or zanamivir in utero during pandemic (H1N1) 2009. Am J Obstet Gynecol. 2013;209(2):130.e1-9. https://doi.org/10.1016/j.ajog.2013.04.007.

48. Khaitov M.R., Laza-Stanca V., Edwards M.R., Walton R.P., Rohde G., Contoli M. et al. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy. 2009;64(3):375-386. https://doi.org/10.1111/j.1398-9995.2008.01826.x.

49. Kuo S.C., Shih S.M., Chien L.H., Hsiung C.A. Collateral Benefit of COVID-19 Control Measures on Influenza Activity, Taiwan. Emerg Infect Dis. 2020;26(8):1928-1930. https://doi.org/10.3201/eid2608.201192.

50. Soo R.J.J., Chiew C.J., Ma S., Pung R., Lee V. Decreased Influenza Incidence under COVID-19 Control Measures, Singapore. Emerg Infect Dis. 2020;26(8):1933-1935. https://doi.org/10.3201/eid2608.201229.

51. Suntronwong N., Thongpan I., Chuchaona W., Budi Lestari F., Vichaiwattana P., Yorsaeng R. et al. Impact of COVID-19 public health interventions on influenza incidence in Thailand. Pathog Glob Health. 2020;114(5):225-227. https://doi.org/10.1080/20477724.2020.1777803.

52. Lei H., Xu M., Wang X., Xie Y., Du X., Chen T. et al. Nonpharmaceutical Interventions Used to Control COVID-19 Reduced Seasonal Influenza Transmission in China. J Infect Dis. 2020;222(11):1780-1783. https://doi.org/10.1093/infdis/jiaa570.

53. Olsen S.J., Azziz-Baumgartner E., Budd A.P., Brammer L., Sullivan S., Pineda R.F. et al. Decreased Influenza Activity During the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1305-1309. https://doi.org/10.15585/mmwr.mm6937a6.

54. Rogers K.C., Wallace J.P., Foster S.L., Finks S.W. Annual influenza vaccination: offering protection beyond infection. South Med J. 2012;105(7):379-386. Available at: https://pubmed.ncbi.nlm.nih.gov/22766667.

55. Lang P.O., Mendes A., Socquet J., Assir N., Govind S., Aspinall R. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55-64. https://doi.org/10.2147/CIA.S25215.

56. Kaiser L., Henry D., Flack N.P., Keene O., Hayden F.G. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis. 2000;30(3):587-589. https://doi.org/10.1086/313696.

57. Hayden F.G., Gubareva L.V., Monto A.S., Klein T.C., Elliot M.J., Hammond J.M. et al. Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000;343(18):1282-1289. https://doi.org/10.1056/NEJM200011023431801.

58. Welliver R., Monto A.S., Carewicz O., Schatteman E., Hassman M., Hedrick J. et al. Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285(6):748-754. https://doi.org/10.1001/jama.285.6.748.

59. Monto A.S., Pichichero M.E., Blanckenberg S.J., Ruuskanen O., Cooper C., Fleming D.M., Kerr С. et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186(11):1582-1588. https://doi.org/10.1086/345722.

60. Hayden F.G., Belshe R., Villanueva C., Lanno R., Hughes C., Small I. et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189(3):440-449. https://doi.org/10.1086/381128.

61. LaForce C., Man C.Y., Henderson F.W., McElhaney J.E., Hampel F.C. Jr., Bettis R. et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2007;29(8):1579-1590. https://doi.org/10.1016/j.clinthera.2007.08.023.

62. Okoli G.N., Otete H.E., Beck C.R., Nguyen-Van-Tam J.S. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS ONE. 2014;9(12):e113633. https://doi.org/10.1371/journal.pone.0113633.

63. Yu Y., Garg S., Yu P.A., Kim H.J., Patel A., Merlin T. et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1) pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis. 2012;55(1):8-15. https://doi.org/10.1093/cid/cis352.

64. Hayden F.G., Atmar R.L., Schilling M., Johnson C., Poretz D., Paar D. et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341(18):1336-1343. https://doi.org/10.1056/NEJM199910283411802.

65. Jackson R.J., Cooper K.L., Tappenden P., Rees A., Simpson E.L., Read R.C., Nicholson K.G. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011;62(1):14-25. https://doi.org/10.1016/j.jinf.2010.10.003.

66. Ye M., Jacobs A., Khan M.N., Jaipaul J., Oda J., Johnson M., Doroshenko A. Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis. BMJ Open. 2016;6(7):e011686. https://doi.org/10.1136/bmjopen-2016-011686.

67. Tsagris V., Nika A., Kyriakou D., Kapetanakis I., Harahousou E., Stripeli F. et al. Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit. J Hosp Infect. 2012;81(1):36-40. https://doi.org/10.1016/j.jhin.2012.02.009.

68. Pannaraj P.S., Tam B., Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol. 2011;31(7):487-493. https://doi.org/10.1038/jp.2010.159.

69. Shinjoh M., Takano Y., Takahashi T., Hasegawa N., Iwata S., Sugaya N. Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection. Pediatr Infect Dis J. 2012;31(11):1119-1123. https://doi.org/10.1097/INF.0b013e318260265a.

70. Higa F., Tateyama M., Tomishima M., Mukatake S., Yamashiro T., Owan T. et al. Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study. Influenza Other Respir Viruses. 2012;6(4):299-303. https://doi.org/10.1111/j.1750-2659.2011.00311.x.

71. Flannery A.H., Thompson Bastin M.L. Oseltamivir Dosing in Critically Ill Patients With Severe Influenza. Ann Pharmacother. 2014;48(8):1011-1018. https://doi.org/10.1177/1060028014535362.


Рецензия

Для цитирования:


Орлова Н.В., Ломайчиков В.В. Роль этиотропной терапии в лечении и профилактике осложнений гриппа в условиях пандемии COVID-19. Медицинский Совет. 2021;(18):86-93. https://doi.org/10.21518/2079-701X-2021-18-86-93

For citation:


Orlova N.V., Lomaychikov V.V. Role of etiotropic therapy in the treatment and prevention of influenza complications amidst the COVID-19 pandemic. Meditsinskiy sovet = Medical Council. 2021;(18):86-93. (In Russ.) https://doi.org/10.21518/2079-701X-2021-18-86-93

Просмотров: 85


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)